Interaksi Eplerenon dan Olmesartan dan hidroklorotiazid

Eplerenon dan Olmesartan dan hidroklorotiazid: kedua label peresepan menandai kombinasi ini dengan bahasa yang paling tegas, seperti kontraindikasi, peringatan kotak hitam, atau instruksi untuk menghindarinya.

Mayor

Jangan dikombinasikan tanpa arahan dokter yang meresepkan. Bahasa label di bawah ini adalah yang paling tegas yang digunakan FDA.

Apa kata label FDA

Dari label Eplerenon (Eplerenone) · berlaku sejak 2025-06-23

Mayor

…• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)…

Kontraindikasiberdasarkan golongan obatLihat label di DailyMed
Mayor

• Concomitant use of potassium supplements or potassium-sparing diuretics ( 4 )

Kontraindikasiberdasarkan golongan obatLihat label di DailyMed
Moderat

• Hyperkalemia: Patients with decreased renal function, diabetes, proteinuria or patients who are taking ACEs and ARBs, NSAIDs or moderate CYP3A inhibitors are at increased risk.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Hyperkalemia The risk of hyperkalemia is higher in patients with impaired renal function, proteinuria, diabetes and those concomitantly treated with ACEs, ARBs, NSAIDs and moderate CYP3A inhibitors.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

ACE Inhibitors and Angiotensin II Receptor Antagonists The risk of hyperkalemia increases when eplerenone is used in combination with an ACE inhibitor and/or an ARB.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Dari label Olmesartan dan hidroklorotiazid (OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE) · berlaku sejak 2026-04-10

Moderat

Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume-or salt-depleted patients ( e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with olmesartan medoxomil and hydrochlorothiazide tablets.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Reduced diuretic, natriuretic and antihypertensive effects; increased risk of renal toxicity ( 7.3 )

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) Olmesartan medoxomil In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including olmesartan…

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Hydrochlorothiazide In some patients the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effects of thiazide diuretics.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

Use of Hydrochlorothiazide with Other Drugs When administered concurrently the following drugs may interact with thiazide diuretics: Antidiabetic drugs (oral agents and insulin): Dosage adjustment of the antidiabetic drug may be required.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.